David A. Eberhard

8.2k citations
51 papers · 5.3k indexed · 1 hit paper · h-index 25

Impact in

  • Oncology top 1%
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Lung Cancer Research Studies
    • Cancer Genomics and Diagnostics

Papers in

    • HER2/EGFR in Cancer Research 11
    • Colorectal Cancer Treatments and Studies 6
    • Cancer Genomics and Diagnostics 9

David A. Eberhard

51 papers receiving 5.1k citations

Hit Papers

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib 2005 · 1.2k citations
1.2k20052026201220194008001.2k

Peers

David A. Eberhard
Comparison fields: 5 of 126
  • Oncology 2.3k
  • Cancer Research 996
  • Pulmonary and Respiratory Medicine 2.1k
  • Genetics 462
  • Molecular Biology 2.5k
Replace Francesco Hofmann with:
Francesco Hofmann Switzerland
Karen Cichowski United States
Dale L. Ludwig United States
Oriol Casanovas Spain
Arnab Chakravarti United States
Ludovic Lacroix France
Raymond S. Yeung United States
Francesca Carlomagno Italy
Laura K. Shawver United States
Erica L. Jackson United States
David A. Eberhard relative to Francesco Hofmann Switzerland Francesco Hofmann's profile →
Citations per field
00.5×1.5×2.3×
Francesco Hofmann · 1×
Citations per year

Countries citing papers authored by David A. Eberhard

Since Specialization
Citations

This map shows the geographic impact of David A. Eberhard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Eberhard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Eberhard more than expected).

Fields of papers citing papers by David A. Eberhard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Eberhard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Eberhard. The network helps show where David A. Eberhard may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Eberhard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Eberhard Line = papers co-authored together David A. Eberhard links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Hit paper breakdown →
20051200
2 2005452
3 2005415
4 2005368
5 1997244
6 2008243
7 1988214
8 1990203
9
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
2000200
10 2006187
11 1989185
12 2013164
13 1987118
14
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.
2002115
15
Alterations of annexin expression in pathological neuronal and glial reactions. Immunohistochemical localization of annexins I, II (p36 and p11 subunits), IV, and VI in the human hippocampus.
1994100
16 201299
17 200996
18 201385
19 199682
20 200779

About David A. Eberhard

David A. Eberhard is a scholar working on Oncology, Cancer Research, Neurology, Complementary and Manual Therapy and Cell Biology, having authored 51 papers that have together received 5.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (11 papers), Lung Cancer Treatments and Mutations (10 papers), Cancer Genomics and Diagnostics (9 papers), Colorectal Cancer Treatments and Studies (6 papers), Vascular Malformations Diagnosis and Treatment (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Molecular Biology Techniques and Applications (4 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). The work is most often cited by research in Oncology (2.3k citations), Cancer Research (996 citations), Pulmonary and Respiratory Medicine (2.1k citations), Genetics (462 citations) and Molecular Biology (2.5k citations). David A. Eberhard has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Ronald W. Holz, Bruce E. Johnson, Somasekar Seshagiri, Thomas Januario, Roy S. Herbst, Jeremy Stinson, Lukas C. Amler, David A. Ramies, David H. Johnson and Ladislau Steiner. Their work appears in journals such as Journal of Clinical Oncology, Applied immunohistochemistry & molecular morphology, Clinical Cancer Research, Neurology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026